Media Coverage header image

Media Coverage

Advanced Search
  • 09022025
    The Wall Street Journal

    More Americans are testing positive for fentanyl use in randomized workplace drug tests, highlighting a persistent challenge for employers. The positive rate for urine tests indicating the presence of the synthetic opioid fentanyl was 1.13% in 2024. That is up from 0.91% in 2023 and double the rate in 2020, according to a recent analysis of more than eight million drug tests by Quest Diagnostics, one of the U.S.’s largest drug-testing labs.

  • 08282025
    HealthTech Magazine

    Jeff Lusby is the general manager of healthcare IT solutions at Quest Diagnostics. With more than 29 years in healthcare IT, Lusby has extensive experience with technology implementations, from the sales journey to installation, support and account management. In his current role, he leads Quest’s Quanum Enterprise Content Solutions software business.

  • 08272025
    Fierce Healthcare

    Corewell Health has signed on to a joint venture with Quest Diagnostics covering inpatient and outpatient lab management and the construction of a new 100,000-square-foot advanced lab facility.

  • 08262025
    Modern Healthcare

    Independent laboratory company Quest Diagnostics and Corewell Health entered a definitive agreement to build a jointly owned lab in Michigan. The Diagnostic Lab of Michigan would be based at the Corewell Health Southfield Center in Southfield, Michigan. It would focus on automated microbiology and high-throughput molecular testing.

  • 08252025
    360Dx

    Quest Diagnostics said on Monday the US Food and Drug Administration has granted breakthrough device designation for the firm's Haystack minimal residual disease (MRD) test. The tumor-informed, whole-exome sequencing assay detects circulating tumor DNA in blood to identify MRD-positive patients with stage II colorectal cancer who have received curative-intent surgical treatment and may benefit from adjuvant therapy. Quest acquired the test when it bought Haystack Oncology in 2023.

  • 08062025
    Inside Precision Medicine

    Quest Diagnostics, a provider of diagnostic information services, has been scaling its efforts in the digital pathology space through an ongoing collaboration with PathAI. “Beyond assisting the pathologist in looking at and identifying problem areas on the slide, there are a lot of AI tools that can help the pathologist become more efficient and work more quickly,” said Chad Richards, president of pathology and medical services at Quest Diagnostics.

  • 08052025
    Modern Healthcare

    Quest Diagnostics has completed its acquisition of some clinical testing assets from Spectra Laboratories, a subsidiary of dialysis company Fresenius Medical Care.

  • 07302025
    360Dx

    During Quest Diagnostics' most recent investor day presentation, President and CEO Jim Davis highlighted the sale of data and data analytics as among the fastest growing businesses within the company. As at Tricore, part of this effort is focused not only on identifying but closing patient care gaps, said David Freeman, VP and general manager of healthcare analytics solutions at the company. Using data generated by a lab, "A health plan can create a standing order for a lab test for a particular patient based on closing a gap in care," he said. If the patient then shows up at a Quest location for another service, "and that standing order exists, we can add that test and close that gap," he said.

  • 07252025
    WJAR-TV (Cranston, RI)

    A new Quest Diagnostics Lab has opened inside a CVS Pharmacy store in Johnston. Company officials gathered at the Putnam Pike store on Friday morning to celebrate its opening, which took place earlier this month. “This lab opened on July 11, and it is the first Quest Diagnostic Lab in Rhode Island and only the second in the nation,” said CVS Pharmacy Senior Vice President, Store and Pharmacy Operations, Jared Tancrelle.

  • 07182025
    Clinical Laboratory Products

    Quest Diagnostics has launched a new PCR-based diagnostic test for the Oropouche virus, enhancing U.S. preparedness for this emerging tropical disease spreading in parts of Latin America and the Caribbean.

  • 07162025
    Clinical Laboratory Products

    Blood-based biomarker tests are revolutionizing the diagnosis and management of Alzheimer’s disease by enabling earlier, faster, and more accessible detection—helping overcome long-standing diagnostic delays, underdiagnosis, and resource constraints. Michael Racke, MD, medical director for neurology at Quest Diagnostics, says that as recently as the 1980s, the telltale plaques and tangles of Alzheimer’s found in the brain could only be detected postmortem, and since there was no treatment, diagnosing the disease wasn’t as critical at the time. Now, tests can detect the disease while the patient is alive, offering a chance at diagnosis and treatment.

  • 07112025
    Men's Health

    It's important to note that anything can be toxic in a certain amount, says Jack Kain, PharmD, director of medical affairs and medical science liaison of drug monitoring and toxicology at Quest Diagnostics. Toxicologists measure toxic amounts in a few different ways. “There's an old saying in toxicology, ‘the dose makes the poison,’ which implies, if you take too much of almost anything, even something as simple as water, it can be toxic,” Dr. Kain says. A high dose of some toxins is necessary to be harmful, while small doses of other toxins can be dangerous.

  • 07112025
    Fierce Biotech

    Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. Developed by Fujirebio, the Lumipulse G test measures the ratio between specific tau and beta amyloid proteins found in the bloodstream to identify patients likely to have plaque buildups in the brain without requiring them to undergo brain scans or spinal tap procedures.

  • 06232025
    Contagion Live

    At the ongoing ASM Microbe 2025, Meghan Starolis, PhD, senior science director of Infectious Diseases at the Quest Diagnostics’ Nichols Institute discussed her presentation, Conquering Antiviral Drug Resistance Via Novel Antivirals & New Testing Methods for Drug Resistance, which looked at genotypic and phenotypic testing and some of the benefits and challenges for each.

  • 06102025
    Fierce Biotech

    Quest Diagnostics will work on a blood test for cancer risk it says may help identify people who could benefit from more frequent screenings using technology developed at the MD Anderson Cancer Center. Dubbed the multi-cancer stratification test, or MCaST, Quest said it has licensed the center’s liquid chromatography and mass spectrometry approach to help build its own offering, which will aim to capture protein biomarkers circulating in the bloodstream that are associated with elevated risks for several different tumors.

  • 05272025
    Today's Clinical Lab

    Alex Louis, senior vice president of enterprise operations and operational excellence at Quest Diagnostics, shares more on how thoughtful planning is essential for successful automation implementation as clinical labs face growing pressure. Clinical laboratories in the US have long operated under significant pressure and challenges, and these have only intensified in recent times. Many laboratory leaders are now facing issues around workflow, staffing, and productivity. Improving the patient and customer experience is also a growing concern, so how can clinical laboratory leaders address these challenges quickly and smoothly?

  • 05222025
    NJBIZ

    Although nearly half of Americans know their streaming platform passwords by heart, only 19% are aware of what their cholesterol score is, according to new data from Quest Diagnostics. As part of its second “Know Your Health” survey, the Secaucus-based testing provider explored what perceptions and priorities adults have for their well-being in 2025. After surveying nearly 2,100 individuals, Quest found that 92% of respondents want to take a more active role in their health care journey. However, many said they face obstacles to receiving care, their doctors do not focus enough on preventive care discussions or have gaps in knowledge on important personal health information.

  • 05132025
    Clinical Laboratory Products

    A new report reveals oncologists are seeing more advanced cancer cases due to screening barriers and are concerned current tests aren’t effective enough for early detection of recurrence. Takeaways: Screening barriers are seen as the leading cause of late-stage cancer diagnoses; Oncologists express concern that current monitoring tools may not detect cancer recurrence early; ctDNA MRD tests, like Quest’s new Haystack MRD, show promise in improving post-treatment cancer surveillance.

  • 05072025
    360Dx

    For decades now, consolidation has been one of the major trends in the clinical laboratory market as major players have grown their businesses through the acquisition of smaller independent and hospital labs. While much of this action has focused on the US market, these firms are looking internationally, as well, striking a number of recent deals to expand their footprints abroad. Last year, for instance, Quest acquired Canadian laboratory firm LifeLabs for roughly $985 million, giving the company a major presence in that country. Karthik Kuppusamy, senior VP of clinical solutions at Quest, said the firm sees opportunities to expand the LifeLabs business by moving into provinces not currently served by the company, winning business currently being done by hospital labs, and introducing new advanced diagnostics into the market.

  • 04102025
    Medical Device Network

    Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related to Alzheimer’s disease in individuals with mild cognitive impairment (MCI) or dementia. The test, known as AD-Detect Abeta 42/40 and p-tau217 Evaluation, is said to combine amyloid beta (AB) 42/40 blood level outcomes, which are determined by Quest’s tandem mass spectrometry techniques with p-tau217 blood levels as measured by an in vitro immunoassay.

  • 04032025
    Practical Patient Care

    Quest Diagnostics has launched a new solution to enhance access to human papillomavirus (HPV) screening, enabling women to identify their risk of cervical cancer. The new offering includes a self-collection option, allowing patients to collect their own specimens for HPV screening in clinical settings. Starting next month, Quest Diagnostics will introduce this self-collection option at its 2,000 patient service centres across the United States, with a physician’s order.

  • 03262025
    Elko Daily Free Press

    The new Quest Diagnostics on Idaho Street in downtown Elko is the company's first foray into Northern Nevada east of Reno, an expansion prompted by a new contract with a major insurer in the region. The lab, at 1074 Idaho St., will have two phlebotomists when fully staffed and expects to draw blood from between 40 to 50 patients a day once operations get fully underway, according to Leanne Delgadillo, sales director for parts of California and Nevada.

  • 03242025
    Clinical Laboratory Products

    The COVID-19 pandemic, which began on March 15, 2020, reshaped healthcare, diagnostics, and public health preparedness, leaving lasting impacts on the industry. The increased public perception of clinical diagnostics has certainly been a silver lining. But it has also exposed ongoing challenges the industry was already coping with—adding additional pressure. “With an aging population, an increase in chronic diseases and delays in care due to the pandemic, the demand for diagnostic testing is on the rise. However, the current workforce is not growing at a pace that can keep up with this demand. Furthermore, there is a shortage of skilled professionals, particularly in specialized areas of laboratory medicine. So, one of the biggest challenges facing the laboratory industry will be staffing and a skilled workforce pipeline,” notes Elizabeth Marlowe, PhD, executive scientific director at Quest Diagnostics.

  • 03232025
    Bloomberg

    More than half of respondents in a recent KPMG survey said they expect AI to change the nature of their business, while nearly 70% plan to invest as much as $250 million in generative AI tools, up from 45% in 2024. Those investments require some risk-taking, but also hard analysis and alignment between finance and IT. Getting to that alignment can be tricky. At Quest Diagnostics, a New Jersey-based medical-testing firm, CFO Sam Samad and CIO Murali Balakumar try to avoid some of these issues by embedding managers in each other’s team. “I’ve got someone who’s reporting to Sam, but who is in all of my meetings,” Balakumar said. Finance has a similar representative in the CIO’s office, he said.

  • 03182025
    Fierce Biotech

    Quest Diagnostics announced it is teaming up with Google Cloud to develop artificial intelligence programs that can personally respond to patients, providers and other customers. That includes generative AI applications that could “connect employees and customers with enterprise-wide knowledge,” the clinical testing giant said in a statement, in addition to helping patients receive insights from their own lab results.

Show 5102550100 per page